Navigation Links
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors. KOS-1584/R1645 showed activity in 32% of patients (13 of 41 evaluable) including activity in patients with non-small cell lung, ovarian, breast, prostate, head and neck and other cancers. Common toxicities were generally low-grade and manageable. Data from this ongoing trial were presented on Sunday, June 3, 2007, in a poster titled, "Phase 1 Trial of KOS-1584 (a Novel Epothilone) Using Two Weekly Dosing Schedules," by Howard Burris, M.D., Sarah Cannon Research Institute, Nashville, TN, at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Epothilones are promising anticancer agents due to their taxane-like mechanism of action and demonstrated activity in taxane resistant tumors," said Dr. Burris. "Kosan's novel epothilone is of particular interest due to its level of antitumor activity in patients with highly refractory disease and manageable side effect profile. This promising compound warrants continued development."

"KOS-1584/R1645 is a highly potent compound with attractive pharmaceutical properties, including a long half-life, large volume of distribution, wide therapeutic index and ease of formulation that has demonstrated encouraging activity in Phase 1 trials," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that KOS-1584/R1645, based on our novel epothilone D backbone, has the potential to be superior to other epothilones currently in development and ultimately emerge as a meaningful competitor in the taxane market. We look forward to initiating a robust Phase 2 clinical program, with the support of our partner Roch
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:5/16/2008)... - Speakers include industry and customer t...re/ -- Velos, Inc., the recognized,leader and trus... this week,hosted a constellation of prestigious a... industry partners at its annual user group meetin...ows customers to internally and,collaboratively ma...
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating ... clinically meaningful extension of progression-fr...zumab to attack both the inside and,outside of the...ckade, -- Data demonstrating activity of TYKERB a...tiple lines of trastuzumab and chemotherapy, LOND...
(Date:5/16/2008)... RARITAN, N.J., May 16 /- Veridex, ...r, Laboratory Corporation of America Holdings,(Lab...ation test for,prostate cancer. The new assay uses...n prostate cancer, detecting the methylation of th...A that occurs primarily in,cancer. Veridex is deve...
(Date:5/15/2008)...- Trial Results Confirm Efficacy for Population Mo...LLE, Calif., May 16 /-,Baye...ceuticals, Inc.,(Nasdaq: ONXX ) today announced t...mproved overall survival by 47.3 percent (HR=0.68;...gion with advanced,hepatocellular carcinoma (HCC),...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Enhanced DNA repair mechanism can cause breast cancer 798 1Enhanced DNA repair mechanism can cause breast cancer 798 2Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 1Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 2Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 3Blood test takes step toward predicting Alzheimers risk Stanford researchers find 3623 4Study reveals a key to blood vessel growth and possible drug target 794 1Study reveals a key to blood vessel growth and possible drug target 794 2Study reveals a key to blood vessel growth and possible drug target 794 3U S Unveils Database of Genetic Clinical Research 3620 1U S Unveils Database of Genetic Clinical Research 3620 2
... 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGX...ous disease and dermatology, today announced that,...by Dr. Paul,Janmey and Dr. Robert Bucki, in collab...niversity, have demonstrated in a series,of in vit...nd known,as CSA-13 shows promise as a potential th...
...ight Weeks Sustained up to 12 Weeks,and Drug Remai...if., July 02, 2007,/PRNewswire-FirstCall/ -- Anesi...follow-up results from a Phase 2 study showing tha...n patients with,moderate-to-severe osteoarthritis ...n that persisted for up to 12 weeks. , "The positi...
Other Medicine Technology:Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 2Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 3Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 2Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 3Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 5
(Date:5/16/2008)...cs want agency to act, not wait years , ,...sumer drug ads on television should include a toll...eport adverse side effects, U.S. health experts su...that advises the U.S. Food and Drug Administration...DA for print ads. At Friday,s meeting, the panel d...
(Date:5/16/2008)...SHINGTON, May 16 /PRNewswire-USNewswire/ -- More t...ns in the Greater Portland, Oregon and,Vancouver, ...tract as,Teamsters., "The Teamsters are pleased t...ract that gives them job protection and a secure r...t Jim Hoffa., The workers, both full-time and par...
(Date:5/16/2008)...efit from calcitriol, an oral form , , F... vitamin D may cut the risk of death for people wi...out one quarter, a new study suggests. , Durin...ose being treated with calcitriol, an oral form of...ath lowered by 26 percent when compared with those...
(Date:5/16/2008)...swire/- "Huh, what did you,say?" is a phrase being...ildren. More than 30 million Americans, that is 1 ...d the numbers are growing at a dramatic rate.,Thir...e form of hearing,loss. An effort to bring more at...t led Kathlyn Maguire, who has profound hearing lo...
Breaking Medicine News(10 mins):Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3
...lder women with depression may have an increased r...New York studied more than 93,600 older women who ...rvational Study (WHI-OS). The WHI-OS is a long-ter...d lifestyle factors influence the risk of heart di...
...cers cause 16,000 deaths each year due to the spre...Previously, the best way to predict whether melano...ness. It was believed the thicker a tumor was, the... many thin melanomas spread and only 40 percent of...
...t study by Taiwanese experts , people buying the p...tually none. St John's Wort, or Hypericum, can ha...arn it can interfere with the effects of other med...d had as much of the active ingredient as claimed,...
... occurs without warning when a woman develops dang...out 5 percent of pregnant women are affected by th...n their urine. If the condition progresses to ecla...result.While doctors can treat the seizures and hi...
Other Medicine News:Health News:Predicting The Risk Of Preeclampsia During Pregnancy 2
The Quinton Q-Stress Cardiac Stress Monitor combines Quinton algorithms, unique baseline wander and muscle artifact filters, and 8000 samples per second to provide the highest ECG fidelity in the ind
...gh in non-invasive cardiac diagnosis, the fully fe...only stress test system that measures T-wave alter...ck provides a quality control facility, this combi...filters the signal ensuring outstanding and noise-...
...90E Automatic Chart Projector makes refracting eas...ts you program up to 33 charts in any order you wi...kened room simply by pressing one button each time...the CP-690E's programmable random access gives you...
The Urchin heart positioner provides excellent access to target coronaries while minimizing hemodynamic instability
Medicine Products: